Bicycle Therapeutics plc American Depositary Shares (BCYC)

FairStock Score: 68/100 — STEADY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.03, providing financial flexibility
• Revenue growth of 1193.3% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of 1.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Bicycle Therapeutics plc American Depositary Shares is a micro-cap healthcare company valued at $340 million. Revenue stands at $73 million, though the company is currently unprofitable. From a quality standpoint, Bicycle shows distressed Altman Z-Score of 1.1 warrants caution and negative ROE indicating losses. Growth dynamics show revenue growing at 1193.3% and profit growth of 61.1%. Our composite FairStock Score of 68/100 reflects above-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Bicycle's 1193% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer